Radioimmunotherapy Market Size, Share, and Trends 2024 to 2034

Radioimmunotherapy Market

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Radioimmunotherapy Market 

5.1. COVID-19 Landscape: Radioimmunotherapy Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Radioimmunotherapy Market, By Indication

8.1. Radioimmunotherapy Market Revenue and Volume Forecast, by Indication, 2024-2034

8.1.1. Hodgkin lymphoma

8.1.1.1. Market Revenue and Volume Forecast (2021-2034)

8.1.2. Leukemia

8.1.2.1. Market Revenue and Volume Forecast (2021-2034)

8.1.3. Non-Hodgkin lymphoma

8.1.3.1. Market Revenue and Volume Forecast (2021-2034)

8.1.4. Multiple Myeloma

8.1.4.1. Market Revenue and Volume Forecast (2021-2034)

8.1.5. Others

8.1.5.1. Market Revenue and Volume Forecast (2021-2034)

Chapter 9. Global Radioimmunotherapy Market, By Target Antigen

9.1. Radioimmunotherapy Market Revenue and Volume Forecast, by Target Antigen, 2024-2034

9.1.1. CD33

9.1.1.1. Market Revenue and Volume Forecast (2021-2034)

9.1.2. CD20

9.1.2.1. Market Revenue and Volume Forecast (2021-2034)

9.1.3. CD52

9.1.3.1. Market Revenue and Volume Forecast (2021-2034)

9.1.4. CD19

9.1.4.1. Market Revenue and Volume Forecast (2021-2034)

9.1.5. Others

9.1.5.1. Market Revenue and Volume Forecast (2021-2034)

Chapter 10. Global Radioimmunotherapy Market, By Radioisotope 

10.1. Radioimmunotherapy Market Revenue and Volume Forecast, by Radioisotope, 2024-2034

10.1.1. Yttrium-90

10.1.1.1. Market Revenue and Volume Forecast (2021-2034)

10.1.2. Lutetium-177

10.1.2.1. Market Revenue and Volume Forecast (2021-2034)

10.1.3. Thallium-201

10.1.3.1. Market Revenue and Volume Forecast (2021-2034)

10.1.4. Iodine-131

10.1.4.1. Market Revenue and Volume Forecast (2021-2034)

10.1.5. Others

10.1.5.1. Market Revenue and Volume Forecast (2021-2034)

Chapter 11. Global Radioimmunotherapy Market, By Administration Route 

11.1. Radioimmunotherapy Market Revenue and Volume Forecast, by Administration Route, 2024-2034

11.1.1. Intrathecal

11.1.1.1. Market Revenue and Volume Forecast (2021-2034)

11.1.2. Intravenous

11.1.2.1. Market Revenue and Volume Forecast (2021-2034)

11.1.3. Intraperitoneal

11.1.3.1. Market Revenue and Volume Forecast (2021-2034)

11.1.4. Others

11.1.4.1. Market Revenue and Volume Forecast (2021-2034)

Chapter 12. Global Radioimmunotherapy Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.1.2. Market Revenue and Volume Forecast, by Target Antigen (2021-2034)

12.1.3. Market Revenue and Volume Forecast, by Radioisotope (2021-2034)

12.1.4. Market Revenue and Volume Forecast, by Administration Route (2021-2034)

12.1.5. U.S.

12.1.5.1. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.1.5.2. Market Revenue and Volume Forecast, by Target Antigen (2021-2034)

12.1.5.3. Market Revenue and Volume Forecast, by Radioisotope (2021-2034)

12.1.5.4. Market Revenue and Volume Forecast, by Administration Route (2021-2034)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.1.6.2. Market Revenue and Volume Forecast, by Target Antigen (2021-2034)

12.1.6.3. Market Revenue and Volume Forecast, by Radioisotope (2021-2034)

12.1.6.4. Market Revenue and Volume Forecast, by Administration Route (2021-2034)

12.2. Europe

12.2.1. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.2.2. Market Revenue and Volume Forecast, by Target Antigen (2021-2034)

12.2.3. Market Revenue and Volume Forecast, by Radioisotope (2021-2034)

12.2.4. Market Revenue and Volume Forecast, by Administration Route (2021-2034)

12.2.5. UK

12.2.5.1. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.2.5.2. Market Revenue and Volume Forecast, by Target Antigen (2021-2034)

12.2.5.3. Market Revenue and Volume Forecast, by Radioisotope (2021-2034)

12.2.5.4. Market Revenue and Volume Forecast, by Administration Route (2021-2034)

12.2.6. Germany

12.2.6.1. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.2.6.2. Market Revenue and Volume Forecast, by Target Antigen (2021-2034)

12.2.6.3. Market Revenue and Volume Forecast, by Radioisotope (2021-2034)

12.2.6.4. Market Revenue and Volume Forecast, by Administration Route (2021-2034)

12.2.7. France

12.2.7.1. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.2.7.2. Market Revenue and Volume Forecast, by Target Antigen (2021-2034)

12.2.7.3. Market Revenue and Volume Forecast, by Radioisotope (2021-2034)

12.2.7.4. Market Revenue and Volume Forecast, by Administration Route (2021-2034)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.2.8.2. Market Revenue and Volume Forecast, by Target Antigen (2021-2034)

12.2.8.3. Market Revenue and Volume Forecast, by Radioisotope (2021-2034)

12.2.8.4. Market Revenue and Volume Forecast, by Administration Route (2021-2034)

12.3. APAC

12.3.1. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.3.2. Market Revenue and Volume Forecast, by Target Antigen (2021-2034)

12.3.3. Market Revenue and Volume Forecast, by Radioisotope (2021-2034)

12.3.4. Market Revenue and Volume Forecast, by Administration Route (2021-2034)

12.3.5. India

12.3.5.1. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.3.5.2. Market Revenue and Volume Forecast, by Target Antigen (2021-2034)

12.3.5.3. Market Revenue and Volume Forecast, by Radioisotope (2021-2034)

12.3.5.4. Market Revenue and Volume Forecast, by Administration Route (2021-2034)

12.3.6. China

12.3.6.1. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.3.6.2. Market Revenue and Volume Forecast, by Target Antigen (2021-2034)

12.3.6.3. Market Revenue and Volume Forecast, by Radioisotope (2021-2034)

12.3.6.4. Market Revenue and Volume Forecast, by Administration Route (2021-2034)

12.3.7. Japan

12.3.7.1. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.3.7.2. Market Revenue and Volume Forecast, by Target Antigen (2021-2034)

12.3.7.3. Market Revenue and Volume Forecast, by Radioisotope (2021-2034)

12.3.7.4. Market Revenue and Volume Forecast, by Administration Route (2021-2034)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.3.8.2. Market Revenue and Volume Forecast, by Target Antigen (2021-2034)

12.3.8.3. Market Revenue and Volume Forecast, by Radioisotope (2021-2034)

12.3.8.4. Market Revenue and Volume Forecast, by Administration Route (2021-2034)

12.4. MEA

12.4.1. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.4.2. Market Revenue and Volume Forecast, by Target Antigen (2021-2034)

12.4.3. Market Revenue and Volume Forecast, by Radioisotope (2021-2034)

12.4.4. Market Revenue and Volume Forecast, by Administration Route (2021-2034)

12.4.5. GCC

12.4.5.1. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.4.5.2. Market Revenue and Volume Forecast, by Target Antigen (2021-2034)

12.4.5.3. Market Revenue and Volume Forecast, by Radioisotope (2021-2034)

12.4.5.4. Market Revenue and Volume Forecast, by Administration Route (2021-2034)

12.4.6. North Africa

12.4.6.1. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.4.6.2. Market Revenue and Volume Forecast, by Target Antigen (2021-2034)

12.4.6.3. Market Revenue and Volume Forecast, by Radioisotope (2021-2034)

12.4.6.4. Market Revenue and Volume Forecast, by Administration Route (2021-2034)

12.4.7. South Africa

12.4.7.1. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.4.7.2. Market Revenue and Volume Forecast, by Target Antigen (2021-2034)

12.4.7.3. Market Revenue and Volume Forecast, by Radioisotope (2021-2034)

12.4.7.4. Market Revenue and Volume Forecast, by Administration Route (2021-2034)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.4.8.2. Market Revenue and Volume Forecast, by Target Antigen (2021-2034)

12.4.8.3. Market Revenue and Volume Forecast, by Radioisotope (2021-2034)

12.4.8.4. Market Revenue and Volume Forecast, by Administration Route (2021-2034)

12.5. Latin America

12.5.1. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.5.2. Market Revenue and Volume Forecast, by Target Antigen (2021-2034)

12.5.3. Market Revenue and Volume Forecast, by Radioisotope (2021-2034)

12.5.4. Market Revenue and Volume Forecast, by Administration Route (2021-2034)

12.5.5. Brazil

12.5.5.1. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.5.5.2. Market Revenue and Volume Forecast, by Target Antigen (2021-2034)

12.5.5.3. Market Revenue and Volume Forecast, by Radioisotope (2021-2034)

12.5.5.4. Market Revenue and Volume Forecast, by Administration Route (2021-2034)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Volume Forecast, by Indication (2021-2034)

12.5.6.2. Market Revenue and Volume Forecast, by Target Antigen (2021-2034)

12.5.6.3. Market Revenue and Volume Forecast, by Radioisotope (2021-2034)

12.5.6.4. Market Revenue and Volume Forecast, by Administration Route (2021-2034)

Chapter 13. Company Profiles

13.1. AbbVie

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Amgen

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Astra Zeneca

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Bayer

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Bristol-Myers Squibb

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Eli Lilly and Company

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Gilead Sciences

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Johnson Johnson

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Merck Co

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Novartis

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms